SYNAPS Dx Demonstrates Physician Burden in Diagnosing Alzheimer's Disease, Value of Highly Accurate Diagnostic Test

Key Facts

ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the release of its white paper, “Clinical Study of Novel Skin Biomarker Test for Alzheimer’s Disease Gains Vigorous Physician Support in Long-Sought Early Detection Breakthrough.”
“Recent data from the Alzheimer’s Association suggests that over half of symptomatic patients are misdiagnosed for AD in the primary care setting, due in part to the lack of access to accurate diagnostic tools.”
“Recent data from the Alzheimer’s Association suggests that over half of symptomatic patients are misdiagnosed for AD in the primary care setting, due in part to the lack of access to accurate diagnostic tools.”
The study found a significant level of need: 9 out of 11 physicians believe that the lack of certainty about the true benefit of upcoming drugs is an unmet need in AD diagnosis 8 out of 11 physicians underscore the utility of an objective, less invasive diagnostic test * 7 out of 12 cited the need for a test that can differentiate AD from other forms of dementia.